2021
Socioeconomic Determinants of the Use of Molecular Testing in Stage IV Colorectal Cancer
Punekar S, Griffin M, Masri L, Roman S, Makarov D, Sherman S, Becker D. Socioeconomic Determinants of the Use of Molecular Testing in Stage IV Colorectal Cancer. American Journal Of Clinical Oncology 2021, 44: 597-602. PMID: 34753883, DOI: 10.1097/coc.0000000000000875.Peer-Reviewed Original ResearchConceptsStage IV colorectal cancerKRAS testingColorectal cancerMedicaid insuranceMultivariable-adjusted Cox proportional hazards modelsStage IV colorectal adenocarcinomaEpidermal growth factor receptor monoclonal antibodiesCox proportional hazards modelMultivariable logistic regression modelAdvanced colorectal cancerEnd Results (SEER) databaseRisk of deathReceptor monoclonal antibodyProportional hazards modelWild-type KRASSocioeconomic disparities persistLogistic regression modelsCRC patientsResults databaseColorectal adenocarcinomaKRAS mutationsHigher median household incomeHazards modelPatientsMolecular testingResponse to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma
Shah P, Punekar S, Pavlick A. Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma. Melanoma Research 2021, 31: 242-248. PMID: 33741813, DOI: 10.1097/cmr.0000000000000730.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsProgression-free survivalHigh-grade immune-related adverse eventsImmune checkpoint inhibitorsOverall survivalDisease progressionAdverse eventsAdvanced melanomaInitial irAEImmune checkpoint inhibitor rechallengeImmune related adverse eventsMedian progression-free survivalUnresectable stage III melanomaMedian overall survivalPercent of patientsRelated adverse eventsStage III melanomaLimited clinical evidenceRisk-benefit profileContinuation of treatmentNYU Langone HealthICI initiationICI rechallengeICI therapyCheckpoint inhibitors
2012
Radical Pleurectomy and Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma
Friedberg J, Culligan M, Mick R, Stevenson J, Hahn S, Sterman D, Punekar S, Glatstein E, Cengel K. Radical Pleurectomy and Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma. The Annals Of Thoracic Surgery 2012, 93: 1658-1667. PMID: 22541196, PMCID: PMC4394024, DOI: 10.1016/j.athoracsur.2012.02.009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCohort StudiesCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesHumansImmunohistochemistryIntraoperative CareMaleMesotheliomaMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPhotochemotherapyPleuraPleural NeoplasmsRisk AssessmentSurvival AnalysisTime FactorsTreatment OutcomeConceptsProgression-free survivalMacroscopic complete resectionRadical pleurectomyIntraoperative photodynamic therapyNonepithelial subtypeMedian survivalComplete resectionEpithelial subtypesStage III/IV diseaseMedian progression-free survivalStage III/IV cancerPhotodynamic therapyLung-sparing approachLung-sparing surgeryMalignant pleural mesotheliomaPostoperative mortalitySystemic therapyPleural mesotheliomaEpithelial diseasePatientsMesotheliomaSubtypesTherapyMonthsSurvival